Overview

N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous fenretinide in treating young patients with recurrent or resistant neuroblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
Nant Operations Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Fenretinide